reports
Korro Announces Oral and Poster Presentations at Upcoming Scientific C...
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences American Society of Gene and Cell Therapy 29th Annual Meeting (ASGCT) TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference3rd International Conference on Ureagenesis Defects and Allied ConditionsEuropean Association for the Study of the Liver (EASL) Congress 2026 CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, to...
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4...
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 15,000 shares of Korro’s common stock at an exercise price of $13.46 per share, the closing price per share of Korro's common stock as rep...
Moody's Ratings affirms Regions' ratings (long-term issuer rating Baa1...
Rating Action: Moody's Ratings affirms Regions' ratings; outlook remains stable. Global Credit Research- 16 Mar 2026. New York, March 16, 2026-- Moody's Ratings has today affirmed Regions Financial Corporation's and its subsidiaries' ratings and assessments, including those of Regions Bank, its lead bank.
- Jonathan Moreland
XRAY DENTSPLY SIRONA INC.
WAT WATERS CORPORATION
TGL. TECNOGLASS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
SFM SPROUTS FARMERS MARKETS INC.
SFBS SERVISFIRST BANCSHARES INC
ROCK GIBRALTAR INDUSTRIES INC.
NSP INSPERITY INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MYGN MYRIAD GENETICS INC.
MLAB MESA LABORATORIES INC.
IP INTERNATIONAL PAPER COMPANY
GOGO GOGO INC.
FFIN FIRST FINANCIAL BANKSHARES INC
COTY COTY INC. CLASS A
NXRT NEXPOINT RESIDENTIAL TRUST INC.
CRG CRH PLC
PLBC PLUMAS BANCORP
BWFG BANKWELL FINANCIAL GROUP
HOG HARLEY-DAVIDSON INC.
MPB MID PENN BANCORP INC.
SSP THE E.W. SCRIPPS COMPANY
SONO SONOS
KOS KOSMOS ENERGY LTD.
AVTR AVANTOR
AHCO INC.
CMTV ADAPTHEALTH
FOUR COMMUNITY BANCORP INC. VT
VERX SHIFT4 PAYMENTS
ADV INC.
EOSE VERTEX
CSU INC.
IMNM ADVANTAGE SOLUTIONS INC (A)
GRNT EOS ENERGY ENTERPRISES INC (A)
ACVA CAPITAL SENIOR LIVING
CPNG IMMUNOME
TKNO GRANIT SKOPKE
QSI ACV AUCTIONS INC.
TCBX COUPANG
BLCO ALPHA TEKNOVA
SMRT INC.
KRRO QUANTUM-SI INC
NCDL THIRD COAST BANCSHARES INC
FG BAUSCH + LOMB CORP
LYEL SMARTRENT INC
KORRO BIO INC
NUVEEN CHURCHILL DIRECT LENDING CORP
F AND G ANNUITIES AND LIFE
INC.
LYELL IMMUNOPHARMA INC.
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
STC STEWART INFORMATION SERVICES CORPORATION
ROCK GIBRALTAR INDUSTRIES INC.
PNNT PENNANTPARK INVESTMENT
PFLT PENNANTPARK FLOATING RATE CAPITAL LTD.
NMFC NEW MOUNTAIN FINANCE CORPORATION
LKFN LAKELAND FINANCIAL CORPORATION
DIN DINE BRANDS GLOBAL INC.
PATK PATRICK INDUSTRIES INC.
IP INTERPUMP GROUP S.P.A.
BBBY BED BATH & BEYOND INC.
BWFG BANKWELL FINANCIAL GROUP
KOS KOSMOS ENERGY LTD.
AEYE AUDIOEYE INC
LCTX LINEAGE CELL THERAPEUTICS
AHCO ADAPTHEALTH
CMTV COMMUNITY BANCORP INC. VT
IMNM IMMUNOME
GRNT GRANIT SKOPKE
FRST PRIMIS FINANCIAL CORP
EFSI EAGLE FINANCIAL SERVICES INC
SMRT SMARTRENT INC
KRRO KORRO BIO INC
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and ...
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a bioph...
Korro Announces Oversubscribed $85 Million Private Placement
Korro Announces Oversubscribed $85 Million Private Placement Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs including reporting clinical data for: KRRO-121 for hyperammonemia in patients with urea cycle disordersKorro’s GalNAc-conjugated oligonucleotide intended for patients with alpha-1 antitrypsin deficiency Company expects proceeds to extend cash runway into the second half of 2028 CAMBRIDGE, Mass., March 09, 2026 (GL...
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
MELI MERCADOLIBRE INC.
HTGC HERCULES CAPITAL INC.
AXTI AXT INC.
LFVN LIFEVANTAGE
HRI HERC HOLDINGS INC.
SXC SUNCOKE ENERGY INC.
CSWC CAPITAL SOUTHWEST CORP.
WINA WINMARK CORP.
AWI ARMSTRONG WORLD INDUSTRIES
PCB INC.
IDYA PACIFIC CITY FINANCIAL CORP
FOUR IDEAYA BIOSCIENCES
LRMR SHIFT4 PAYMENTS
PCVX INC.
ABCL LARIMAR THERAPEUTICS INC
ACVA VAXCYTE
TBBK ABCELLERA BIOLOGICS
FSCO ACV AUCTIONS INC.
ZURA THE BANCORP
NPWR INC.
EDSA FS CREDIT OPPORTUNITIES CORP.
LAW ZURA BIO LTD
NET POWER INC
EDESA BIOTECH INC
CS DISCO INC
Korro to Present at the TD Cowen 46th Annual Health Care Conference
Korro to Present at the TD Cowen 46th Annual Health Care Conference CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 46th Annual Health Care Conference being held in Boston, MA at the Boston Marriott Copley Place on March 2nd – 4th, 2026. Dr. Aiyar’s presentation will take place on Tuesday, March 3, 2026, at 11...
- Jonathan Moreland
SCSC SCANSOURCE INC.
PSEC PROSPECT CAPITAL CORPORATION
MSCI MSCI INC. CLASS A
MOH MOLINA HEALTHCARE INC.
MMS MAXIMUS INC.
KVHI KVH INDUSTRIES INC.
HTGC HERCULES CAPITAL INC.
FAF FIRST AMERICAN FINANCIAL CORPORATION
BMI BADGER METER INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
PRU PRUDENTIAL FINANCIAL INC.
ASA ASA
WY WEYERHAEUSER COMPANY
MDU MDU RESOURCES GROUP INC
MEDP MEDPACE HOLDINGS INC.
SAH SONIC AUTOMOTIVE INC. CLASS A
TSI TCW STRATEGIC INCOME FUND INC.
PLBC PLUMAS BANCORP
GRF EAGLE CAPITAL GROWTH FUND INC
CNDT CONDUENT INC.
MSFT MICROSOFT CORPORATION
SSTI SHOTSPOTTER
ZIVO ZIVO BIOSCIENCE
KKR INC.
BOTJ KKR & CO. INC.
AXR BANK OF THE JAMES FINANCIAL GROUP INC.
TENB AMREP
AVTR TENABLE HOLDINGS
CMTV AVANTOR
VERX INC.
BIGC COMMUNITY BANCORP INC. VT
SLQT VERTEX
DLHC INC.
AFRM BIGCOMMERCE HOLDINGS
FLYW SELECTQUOTE
CHRW INC.
TBBK DALEIGH HOLDINGS CORP
QDEL AFFIRM HOLDINGS
IE FLYWIRE CORP
CHUC C.H. ROBINSON WORLDWIDE
RXO_w INC.
GTE THE BANCORP
CNVS INC.
COCH QUIDEL CORP
ASST IVANHOE ELECTRIC INC
SPGI CHARLIES HLDGS INC
EKSO RXO INC
NDAQ GRAN TIERRA ENERGY INC.
LNZA CINEVERSE CORP
ANZU SPECIAL ACQUISITION CORP I
ASSET ENTITIES INC.
MCGRAW HILL FINANCIAL INC
EKSO BIONICS HOLDINGS INC.
THE NASDAQ OMX GROUP
INC.
LANZATECH GLOBAL INC
Genelux Corporation to Participate in Upcoming Conferences
Genelux Corporation to Participate in Upcoming Conferences WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences. Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.TD Cowen 46th Annual Health Care Conference: Th...
- Jonathan Moreland
CINF CINCINNATI FINANCIAL CORPORATION
ASA ASA
MDU MDU RESOURCES GROUP INC
MEDP MEDPACE HOLDINGS INC.
NWPP NEW PEOPLES BANKSHARES INC.
ZIVO ZIVO BIOSCIENCE
SONO INC.
JYNT SONOS
RXO_w THE JOINT
VANI RXO INC
GTE VIVANI MEDICAL INC
CNVS GRAN TIERRA ENERGY INC.
COCH CINEVERSE CORP
MXF ANZU SPECIAL ACQUISITION CORP I
GF THE MEXICO FUND
EKSO INC.
THE NEW GERMANY FUND
INC.
EKSO BIONICS HOLDINGS INC.
Regions Financial Corp: 1 director
A director at Regions Financial Corp sold 36,000 shares at 28.780USD and the significance rating of the trade was 89/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Korro to Host Virtual Analyst Day on January 27, 2026
Korro to Host Virtual Analyst Day on January 27, 2026 - Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m. – 10 a.m. ET, with members of the Korro management team, Bruce Scharschmidt, MD,...
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by...
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT. A live webcast of the fireside ...
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Pu...
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux. The gross proceeds to Genelux from the offering are expected to be approximately $20.0 million, before deducting underwriting disc...
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on the “Events & Presentations” page ...
Genelux Corporation Announces Proposed Public Offering of Common Stock
Genelux Corporation Announces Proposed Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten public offering of its common stock. In addition, Genelux expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the proposed offering. All shares are being offered by Genelux. The proposed offering is subject to ...
Genelux Corporation Reports Encouraging Interim Data of Systemic Admin...
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials -- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In platinum-relapsed or platinum-refractory advanced SCLC, two of three partial responses (PRs) occurred in the highest dose cohort tested as of the data review cutoff date (tumor shrinkage of ~55% and ~85%), with three PRs out of nine subjects (33%) across ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.